Peer-reviewedLicence not statedTherapeutic Delivery
An evaluation of mitapivat for the treatment of non-transfusion-dependent alpha- and beta-thalassemia
- 1Division of Hematology Oncology, Hospital of the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
- 2Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Related
- Serum β2-microglobulin as a marker of renal tubular damage in transfusion-dependent β-thalassemia.
- Optimizing outcomes and accessibility of matched sibling donor transplant for transfusion-dependent thalassemia in LMICs
- Growth Profile and Endocrine Dysfunction in Children Aged 2-10 Years With Transfusion-Dependent β-Thalassemia Major.
- Correlation Between Serum Ferritin and Electrocardiographic and Echocardiographic Markers of Cardiac Dysfunction in Children With Transfusion-Dependent β-Thalassemia Major.
- When Every Test Fails: Multifocal Grade 1 Ileal Neuroendocrine Tumors Causing Transfusion-Dependent Obscure Overt Gastrointestinal Bleeding.
BibTeX
@article{cheng2026evaluation,
title = {{An evaluation of mitapivat for the treatment of non-transfusion-dependent alpha- and beta-thalassemia}},
author = {Aaron N. Cheng and Hanny Al-Samkari},
journal = {Therapeutic Delivery},
year = {2026},
month = oct,
doi = {10.1080/20415990.2026.2742638},
url = {https://doi.org/10.1080/20415990.2026.2742638},
}
RIS
TY - JOUR
TI - An evaluation of mitapivat for the treatment of non-transfusion-dependent alpha- and beta-thalassemia
AU - Aaron N. Cheng
AU - Hanny Al-Samkari
PY - 2026
DA - 2026/10/06
JO - Therapeutic Delivery
DO - 10.1080/20415990.2026.2742638
UR - https://doi.org/10.1080/20415990.2026.2742638
SN - 2041-5990
SN - 2041-6008
ER -